Eli Lilly Says Higher Trulicity Doses Reduced A1C, Weight in People with Type 2 Diabetes

By Michael Dabaie

Eli Lilly & Co. said new 36-week data showed higher investigational doses of Trulicity were well-tolerated and led to A1C reductions up to 1.9% and weight reductions up to 10.4 pounds in people with type 2 diabetes.

The results from Lilly's Award-11 trial, which evaluated higher investigational doses of Trulicity, 3 mg and 4.5 mg, compared to Trulicity 1.5 mg, were published in the Journal of the Endocrine Society.

The trial "confirmed our expectations that a higher investigational dose of Trulicity would lead to superior blood glucose and weight reductions in people with type 2 diabetes compared to Trulicity 1.5 mg," said Juan Pablo Frias, medical director and principal investigator at National Research Institute.

Results at 52 weeks were consistent with the 36-week results and further details will be disclosed at a later date, Lilly said. The Award-11 results have been submitted to regulatory authorities in the U.S. and Europe for review.

Write to Michael Dabaie at michael.dabaie@wsj.com

(END) Dow Jones Newswires

May 08, 2020 15:30 ET (19:30 GMT)

Eli Lilly (NYSE:LLY)
Historical Stock Chart
From Mar 2024 to Apr 2024